Geode Capital Management LLC Boosts Stock Holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Geode Capital Management LLC boosted its stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 2.2% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 912,599 shares of the medical instruments supplier’s stock after purchasing an additional 19,972 shares during the quarter. Geode Capital Management LLC owned about 2.09% of Harvard Bioscience worth $2,455,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of HBIO. Bank of New York Mellon Corp lifted its position in shares of Harvard Bioscience by 13.0% in the second quarter. Bank of New York Mellon Corp now owns 274,635 shares of the medical instruments supplier’s stock worth $783,000 after buying an additional 31,505 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new stake in Harvard Bioscience in the 2nd quarter worth approximately $31,000. Rhumbline Advisers raised its holdings in shares of Harvard Bioscience by 24.9% during the 2nd quarter. Rhumbline Advisers now owns 47,753 shares of the medical instruments supplier’s stock worth $136,000 after acquiring an additional 9,512 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Harvard Bioscience by 6.1% during the 2nd quarter. Renaissance Technologies LLC now owns 745,278 shares of the medical instruments supplier’s stock valued at $2,124,000 after acquiring an additional 42,800 shares during the last quarter. Finally, Gabelli Funds LLC purchased a new position in shares of Harvard Bioscience in the second quarter valued at $128,000. Hedge funds and other institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Price Performance

Harvard Bioscience stock opened at $2.15 on Wednesday. Harvard Bioscience, Inc. has a 52-week low of $1.95 and a 52-week high of $4.99. The company has a quick ratio of 0.91, a current ratio of 2.06 and a debt-to-equity ratio of 0.52. The firm’s fifty day moving average is $2.23 and its 200 day moving average is $2.61. The company has a market cap of $93.78 million, a price-to-earnings ratio of -6.51 and a beta of 1.27.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.